BIAF (bioAffinity Technologies) LT-Debt-to-Total-Asset: 0.14 (As of Mar. 2026)

What is bioAffinity Technologies LT-Debt-to-Total-Asset?

bioAffinity Technologies BIAF -1.48% 44 LT-Debt-to-Total-Asset is 0.14 as of Mar. 2026. GuruFocus rates BIAF with a GF Score™ of 44/100 and a GF Value™ of $4.26 (Possible Value Trap). The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. bioAffinity Technologies's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.14.

bioAffinity Technologies's long-term debt to total assets ratio increased from Mar. 2025 (0.13) to Mar. 2026 (0.14). It may suggest that bioAffinity Technologies is progressively becoming more dependent on debt to grow their business.

bioAffinity Technologies (NAS:BIAF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

bioAffinity Technologies LT-Debt-to-Total-Asset Related Terms

bioAffinity Technologies LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for bioAffinity Technologies's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

bioAffinity Technologies LT-Debt-to-Total-Asset Chart

bioAffinity Technologies Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.11

0.00

0.14

0.12

0.07

bioAffinity Technologies Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.13	0.07	0.03	0.07	0.14

44GF Score

bioAffinity Technologies Inc BIAF

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

bioAffinity Technologies LT-Debt-to-Total-Asset Calculation

bioAffinity Technologies's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	0.777	/	10.961
	=	0.07

bioAffinity Technologies's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	1.099	/	7.945
	=	0.14

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.14 mean?

bioAffinity Technologies (BIAF) has a LT-Debt-to-Total-Asset of 0.14 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on bioAffinity Technologies and its competitors.

Is bioAffinity Technologies' LT-Debt-to-Total-Asset too high?

bioAffinity Technologies' current LT-Debt-to-Total-Asset is 0.14. Overall, bioAffinity Technologies has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does bioAffinity Technologies' LT-Debt-to-Total-Asset compare to NDRA and ISPC?

bioAffinity Technologies' LT-Debt-to-Total-Asset of 0.14 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Diagnostics & Research company?

A good LT-Debt-to-Total-Asset depends on the Medical Diagnostics & Research industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on bioAffinity Technologies and its competitors. bioAffinity Technologies's current LT-Debt-to-Total-Asset is 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is bioAffinity Technologies stock overvalued right now?

Based on GuruFocus' analysis, bioAffinity Technologies (BIAF) is currently considered Possible Value Trap. The stock's GF Value™ is $4.26, compared to a current price of $0.76 — trading 82.2% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.14. bioAffinity Technologies' overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For bioAffinity Technologies (BIAF), the current LT-Debt-to-Total-Asset is 0.14 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is bioAffinity Technologies (BIAF) Overvalued in 2026?

Based on GuruFocus' analysis, bioAffinity Technologies stock appears to be undervalued. The current stock price of $0.76 is trading 82.2% below its estimated GF Value™ of $4.26. GuruFocus considers bioAffinity Technologies to be Possible Value Trap.

Key valuation signals for BIAF:

LT-Debt-to-Total-Asset: 0.14
GF Value™: $4.26 vs. price of $0.76 (82.2% below fair value)
GF Score™: 44/100 with 3 warning signs

No single metric tells the full story. See the BIAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

bioAffinity Technologies Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies NDRA ISPC ADVB MBAI FUNI IVRO PRPH XWEL IDTA NSTM TMO DHR SHSE:603259 XSWX:LONN IDXX A NTRA WAT IQV ILMN

Address 3300 Nacogdoches Road, Suite 216, San Antonio, TX, USA, 78217

Website https://www.bioaffinitytech.com

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

44GF Score

Get the complete analysis for BIAF

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76

Price

$4.26

GF Value

View BIAF Analysis

See LT-Debt-to-Total-Asset data for all stocks →